Analysts predict that Insulet Co. (NASDAQ:PODD) will announce ($0.07) earnings per share for the current quarter, Zacks reports. Ten analysts have made estimates for Insulet’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.15). Insulet reported earnings per share of ($0.16) during the same quarter last year, which indicates a positive year-over-year growth rate of 56.3%. The company is scheduled to report its next earnings report on Monday, February 26th.

According to Zacks, analysts expect that Insulet will report full-year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.50) to ($0.35). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.62) to $0.30. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Insulet.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same period in the prior year, the company earned ($0.05) EPS. Insulet’s revenue was up 28.4% on a year-over-year basis.

A number of research firms have commented on PODD. BidaskClub lowered shares of Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Canaccord Genuity reaffirmed a “hold” rating and set a $50.00 price objective on shares of Insulet in a research note on Wednesday, September 27th. Barclays upped their price objective on shares of Insulet from $70.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 20th. Robert W. Baird upped their price objective on shares of Insulet from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Finally, Wedbush reaffirmed a “buy” rating and set a $65.00 price objective (up from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $61.07.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were bought at an average price of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 1.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Insulet by 11.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 235 shares during the period. SG Americas Securities LLC acquired a new position in shares of Insulet in the 2nd quarter valued at about $180,000. Wrapmanager Inc. acquired a new position in Insulet in the second quarter worth approximately $217,000. RNC Capital Management LLC acquired a new position in Insulet in the second quarter worth approximately $225,000. Finally, Trexquant Investment LP acquired a new position in Insulet in the third quarter worth approximately $242,000.

Insulet (NASDAQ PODD) traded up $1.03 during mid-day trading on Wednesday, reaching $69.76. 471,217 shares of the company’s stock were exchanged, compared to its average volume of 544,318. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65. Insulet has a 52 week low of $36.68 and a 52 week high of $72.99.

COPYRIGHT VIOLATION WARNING: “Insulet Co. (PODD) Expected to Announce Earnings of -$0.07 Per Share” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/09/insulet-co-podd-expected-to-announce-earnings-of-0-07-per-share.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Stock Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related stocks with our FREE daily email newsletter.